Sofinnova Partners — 2022 Investments
11 investments dated 2022 · listed companies and verified rows first · show all
Biosyntia develops microbial fermentation processes using proprietary engineered microorganisms to produce natural ingredients such as fermented vitamins and plant-derived bioactives.
BiotechCleantechFoodTechNew MaterialsCopenhagen, DK
Hans Genee(Founder)Morten Sommer(Founder)Martin(Chief Executive Officer)Andreas Hougaard Laustsen
Co-investorsEuropean Circular Bioeconomy FundNovo Holdings
Inspirna is a clinical-stage biopharmaceutical company developing novel cancer drugs that target previously undruggable drivers of metastasis using its proprietary miRNA-DRIVEr platform.
BiotechHealthtechMedical DevicesNew York, US
Sohail Tavazoie(Co-Founder & Chair of Scientific Advisory Board)Masoud Tavazoie(Co-Founder & Advisor)in
Co-investorsVivo CapitalSands Capital VenturesStart CapitalNovo Holdings
Microphyt develops microalgae-based ingredients and products for nutrition, dietary supplements, and personal care using proprietary bio-reactor technology.
BiotechFoodTechHealthtechNew MaterialsWellness & Fitness
Arnaud Muller-FeugaVincent Usache(Managing Director)in
Co-investorsBpifranceSupernova Invest
Nephris is an Italian company presenting an investor relations page with corporate documents such as its chamber of commerce record and annual financial statement; the site references a therapeutic objective, indicating a focus in the life sciences/biotech field.
BiotechDigital Health
SafeHeal is a medical device manufacturer developing anastomosis protection devices for colorectal surgery.
BiotechDigital HealthHealthtechMedical DevicesFrance, FR
Chris Richardson(President & CEO)inKarl Blohm(VP, International)inScott DePierro(VP, US Operations)inMarcos Velez-Duran(VP, Regulatory Affairs and Quality)inBrent Metzler(CFO)Michael Augelli(VP, R&D, Manufacturing)in
Co-investorsAsabys Partners
Elicit Plant develops agricultural solutions that trigger plants' natural defenses to help field crops resist water stress and adapt to climate change.
AgTechBiotechClimate Tech
Olivier Goulay(Founder)in
Co-investorsEuropean Circular Bioeconomy Fund
F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAdvent Life SciencesAisling CapitalAMR Action FundAstellas Venture Management LLCBrace PharmaSunstone Capital+4 more
GFBiochemicals develops plant-based chemical ingredients derived from levulinate technology to replace harmful petrochemical components in consumer products such as shampoos, detergents, and cosmetics.
BiotechCircular EconomyCleantechClimate TechNew MaterialsAix en Provence, FR
Prometheus Materials develops low-carbon cement and concrete technology, marketed as ProZERO, using algae-based biotechnology as a replacement for portland cement in ready-mix and construction applications.
CleantechConstruction TechNew MaterialsLongmont, US
Loren Burnett(President, CEO and Co-founder)inSherri Cook(Advisor and Co-founder)inMija Hubler(Engineering Advisor and Co-founder)inWil Srubar III(Technology Advisor and Co-founder)inJaclyn Gruber(Chief Marketing Officer)in
BoardJosko Bobanovic(Director)
Co-investorsAutodesk Foundation
Protera builds functional protein ingredients for the food industry using its madi platform, which combines generative AI and computational biology to design novel proteins produced through precision fermentation.
AI & Machine LearningBiotechFoodTech
Co-investorsSOSV
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Mablink Bioscience
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.























